Back
Speaker illustration

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

Member of:

European Society of Cardiology

Presentations

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Lipid-lowering therapy and the atheroma

Access
Like
Thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.

Event: ESC Congress 2020

Topic: Prevention

Session: PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Access
Like
Thumbnail

Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada

Event: ESC Congress 2020

Topic: Treatment

Session: Coronary Artery Disease (Chronic) ePosters

Access
Like
Thumbnail

Clinical implications for post-ACS patients

Event: ESC Congress 2018

Topic: Treatment

Session: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Access
Like
Thumbnail

Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study

Event: ESC Congress 2016

Topic: Thrombosis and platelets

Session: Dual antiplatelet therapy: the long and the short of it!

Access
Like
Thumbnail

How might PCSK9 inhibition change this debate?

Event: ESC CONGRESS 2014

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: New frontiers in cholesterol management in high cardiovascular risk patients

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources